地舒单抗注射液治疗绝经后骨质疏松症的临床疗效观察

Clinical Curative Effect Observation of Denosumab Injection in the Treatment of Postmenopausal Osteoporosis

目的:分析地舒单抗注射液治疗绝经后骨质疏松症(PMOP)的临床疗效。方法:选取2020年10月至2021年4月南昌市洪都中医院接收的210例PMOP患者,采用半随机对照试验方法,分为对照组、试验组1、试验组2,各70例,对照组接受芪骨胶囊治疗,试验组1接受地舒单抗注射液治疗,试验组2接受二者联合治疗。比较三组治疗前、治疗6个月、12个月时腰椎、股骨颈骨密度(BMD),中医证候积分,骨质疏松四项[骨钙素(OST)、总Ⅰ型胶原氨基端延长肽(PINP)、β胶原特殊序列(β-CTX)、25-羟基维生素D]。结果:治疗6个月和12个月时,三组腰椎和股骨颈BMD逐渐提高,且试验组2高于对照组、试验组1;三组中医证候积分逐渐下降,且试验组2低于对照组、试验组1(P<0.05);治疗6个月和12个月时,三组OST、PINP、β-CTX逐渐下降,且试验组2低于对照组、试验组1;三组25-羟基维生素D逐渐升高,且试验组2高于对照组、试验组1(P<0.05)。对照组、试验组1治疗后各指标比较,差异无统计学意义(P>0.05)。结论:在芪骨胶囊常规治疗基础上,地舒单抗注射液治疗PMOP可提高BMD,减轻患者症状,改善骨质疏松四项指标。

Objective:To analyze the clinical efficacy of denosumab injection in the treatment of postmenopausal osteoporosis(PMOP).Methods:From October 2020 to April 2021,210 PMOP patients received by Nanchang Hongdu Hospital of Traditional Chinese Medicine were selected and divided into a control group,an experimental group 1,and an experimental group 2 by a semi-randomized controlled trial method,with 70 cases in each group.The control group received qigu capsules treatment,the experimental group 1 received denosumab injection,and the experimental group 2 received the combined treatment of both.The bone mineral density of lumbar spine and femoral neck(BMD),TCM syndrome score,and four items of osteoporosis[osteocalcin(OST),total collagen type I amino-terminal extension peptide(PINP),β-collagen special sequence(β-CTX),25-hydroxy vitamin D]was compared between the three groups before treatment,6 months and 12 months after treatment.Results:After 6 months and 12 months of treatment,the BMD of the lumbar spine and femoral neck of the three groups gradually increased,and the experimental group 2 was higher than the control group and the experimental group 1;the TCM syndrome scores of the three groups gradually decreased,and the experimental group 2 was lower than the control group and experimental group 1(P<0.05);after 6 months and 12 months of treatment,OST,PINP andβ-CTX in the three groups gradually decreased,and the experimental group 2 was lower than the control group and experimental group 1;the 25-hydroxyl Vitamin D in the three groups gradually increased,and the experimental group 2 was higher than the control group and experimental group 1(P<0.05).There was no significant difference between the control group and experimental group 1 after treatment in each index(P>0.05).Conclusion:On the basis of the routine treatment of qigu capsules,densumab injection in the treatment of PMOP can improve BMD,alleviate the symptoms of patients,and improve the four indicators of osteoporosis.